Efficacy of Oropharyngeal Exercises for Patients With Obstructive Sleep Apnea Using Mandibular Advancement Device

Sponsor
National Cheng-Kung University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06103630
Collaborator
(none)
20
1
2
50
0.4

Study Details

Study Description

Brief Summary

Oropharyngeal muscle training has emerged as a novel adjunctive treatment approach, involving training of the swallowing muscle group and tongue muscles to prevent tongue collapse, reduce tongue base volume during sleep, and strengthen muscle tension.

Therefore, the objective is to assess changes in oropharyngeal muscle strength, ultrasonographic tongue morphology, severity of sleep related breathing interruptions, clinical symptoms, and correlations among these factors. Oropharyngeal muscle training for patients with residual OSA using MAD can significantly 1. increase muscle strength and endurance. 2. reduce the severity of sleep-related breathing interruptions. 3. decrease clinical symptoms. 4. improve tongue morphology.

Condition or Disease Intervention/Treatment Phase
  • Other: Oropharyngeal Exercises
  • Other: Mandibular advancement device
N/A

Detailed Description

Background:

Obstructive Sleep Apnea (OSA) refers to recurrent upper airway blockages during sleep, leading to symptoms like snoring, 2 interrupted breathing causing micro-awakenings, daytime sleepiness, impaired concentration, and various chronic conditions. The Mandibular Advancement Device (MAD) is a treatment method for OSA, suitable for mild to moderate cases and CPAP noncompliance. However, clinical use of MAD sometimes falls short in comprehensively alleviating the clinical symptoms of obstructive sleep apnea. Therefore, oropharyngeal muscle training has emerged as a novel adjunctive treatment approach, involving training of the swallowing muscle group and tongue muscles to prevent tongue collapse, reduce tongue base volume during sleep, and strengthen muscle tension. This training aims to increase overall respiratory tract rigidity and improve muscle responsiveness during reduced blood oxygen levels.

Given that some patients do not achieve the expected outcomes after MAD therapy, whether oropharyngeal muscle training can enhance treatment effects becomes a research focus. Thus, this study aims to apply oropharyngeal muscle training to patients who have not achieved the anticipated results following MAD treatment. The objective is to assess changes in oropharyngeal muscle strength, ultrasonographic tongue morphology, severity of sleep related breathing interruptions, clinical symptoms, and correlations among these factors.

Methods:

Fifty diagnosed OSA patients using MAD and consenting to participate are recruited. Patients agreeing to undergo 12 weeks of oropharyngeal muscle training form the treatment group, while those not agreeing form the control group. The treatment group undergoes 12 weeks of training, with weekly in-person follow-ups for treatment intensity adjustment and home-based sessions (30 mins, 1-3 times/day, 3-5 days/week) for a total of 12 weeks. The control group continues MAD therapy. Both groups undergo evaluations of muscle strength and endurance, various sleep physiological tests, ultrasonographic imaging of the tongue and oropharynx, and sleep questionnaire tests before and after the 12- week training period.

Expected Outcomes:
  1. Oropharyngeal muscle training may increase muscle strength and endurance.

  2. Oropharyngeal muscle training may reduce the severity of sleep-related breathing interruptions.

  3. Oropharyngeal muscle training may decrease clinical symptoms.

  4. Oropharyngeal muscle training may improve tongue morphology.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy of Oropharyngeal Exercises for Patients With Residual Obstructive Sleep Apnea Using Mandibular Advancement Device
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2027
Anticipated Study Completion Date :
Dec 31, 2027

Arms and Interventions

Arm Intervention/Treatment
Sham Comparator: Control group

Mandibular advancement device

Other: Mandibular advancement device
Mandibular advancement device

Experimental: Intervention group

Participants will received 1-2 times a week, 12-week-intervention of Oropharyngeal Exercises and Mandibular advancement device.

Other: Oropharyngeal Exercises
Oropharyngeal Exercises

Other: Mandibular advancement device
Mandibular advancement device

Outcome Measures

Primary Outcome Measures

  1. Apnea-hypopnea -index [Baseline to 12 weeks]

    Assessed using Polysomnography (PSG). The average apnea and hypopnea events per hour, oxygen saturation index and the snoring index will be obtained during the sleep test(PSG).

Secondary Outcome Measures

  1. Tongue muscle strength [Baseline to 12 weeks]

    The maximal muscle strength of genioglossus muscles using The Iowa Oral Performance Instrument (IOPI) system, model 2.2 (Northwest, Co., LLC, Carnation, WA, USA) (kPa)

  2. Jaw strength [Baseline to 12 weeks]

    Jaw strength will be measured using a 'handheld' dynamometer (MicroFET○R2, Hoggan Scientific, USA). The data will be presented in kilogram-weight. The minimum score is 0 and a higher score indicates stronger in jaw strength.

  3. Tongue muscle endurance [Baseline to 12 weeks]

    The endurance of the genioglossus muscles using The Iowa Oral Performance Instrument (IOPI) system, model 2.2 (Northwest, Co., LLC, Carnation, WA, USA) (in seconds).

  4. Tongue Muscle Thickness [Baseline to 12 weeks]

    Sonography will be performed over the participant's neck region to assess the changes in tongue muscle thickness during normal breathing.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • OSA patients

  • Aged over 20 years

  • Wearing MAD (The amount of MAD is at least 50% of the maximum amount that the patient can achieve.)

Exclusion Criteria:
  • Body Mass Index (BMI) ≧ 35

  • Pregnancy

  • Severe obstructive or restrictive lung disease

  • Exercise with high-risk cardiovascular disease

  • History of central or peripheral neurological disease resulting in an inability to perform exercise prescriptions

  • Musculoskeletal or psychological disorders that prevent the performance of exercise prescriptions

  • Chronic illnesses that are ongoing or not yet controlled

Contacts and Locations

Locations

Site City State Country Postal Code
1 National Cheng Kung University Hospital Tainan Taiwan 704

Sponsors and Collaborators

  • National Cheng-Kung University Hospital

Investigators

  • Principal Investigator: Ching-Hsia Hung, PhD, National Cheng Kung University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
National Cheng-Kung University Hospital
ClinicalTrials.gov Identifier:
NCT06103630
Other Study ID Numbers:
  • B-ER-112-396
First Posted:
Oct 27, 2023
Last Update Posted:
Oct 27, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by National Cheng-Kung University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 27, 2023